[Form 4] Tenon Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Tenon Medical's Chief Innovation Officer reported buying additional stock and warrants in the company. On November 14, 2025, the officer purchased 19,455 shares of common stock in an at-the-market private investment in public equity transaction at a combined price of $1.285 per share and accompanying warrant.

The officer also received warrants to purchase up to 19,455 shares of common stock at an exercise price of $1.16 per share, exercisable starting November 14, 2025 and expiring November 14, 2028. Following this transaction, the officer directly beneficially owned 157,569 shares and indirectly beneficially owned 350,765 shares through SiVantage, Inc.

Insider Trade Summary

3 transactions reported

Net Buy 3 txns

Insider Geist Wyatt D.

Role Chief Innovation Officer

Bought 38,910 shs ($0.00)

Type	Security	Shares	Price	Value
Purchase	Common Stock Purchase Warrant	19,455	$0.00	--
Purchase	Common stock	19,455	$0.00	--
holding	Common stock	--	--	--

Holdings After Transaction: Common Stock Purchase Warrant — 19,455 shares (Direct); Common stock — 157,569 shares (Direct); Common stock — 350,765 shares (Indirect, By SiVantage, Inc.)

Footnotes (1)

1. On November 10, 2025, the Issuer entered into a Securities Purchase Agreement for an at-the-market private investment in public equity transaction, in which the reporting person purchased 19,455 shares of common stock of the Issuer and warrants to purchase up to 19,455 shares of common stock of the Issuer. The purchase price for each share of common stock and accompanying warrant was $1.285. The offering closed on November 14, 2025. Reflects the reporting person's indirect interest in 710,300 shares owned by SiVantage, Inc., a corporation in which the reporting person has a 49.38% equity interest.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Geist Wyatt D.

(Last) (First) (Middle)

104 COOPER CT.

(Street)

LOS GATOS CA 95032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenon Medical, Inc. [ TNON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Innovation Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	11/14/2025		P		19,455	A	(1)	157,569	D
Common stock								350,765	I	By SiVantage, Inc.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Purchase Warrant	$1.16	11/14/2025		P		19,455		11/14/2025	11/14/2028	Common Stock	19,455	(1)	19,455	D

Explanation of Responses:

1. On November 10, 2025, the Issuer entered into a Securities Purchase Agreement for an at-the-market private investment in public equity transaction, in which the reporting person purchased 19,455 shares of common stock of the Issuer and warrants to purchase up to 19,455 shares of common stock of the Issuer. The purchase price for each share of common stock and accompanying warrant was $1.285. The offering closed on November 14, 2025.

2. Reflects the reporting person's indirect interest in 710,300 shares owned by SiVantage, Inc., a corporation in which the reporting person has a 49.38% equity interest.

	/s/ Wyatt Geist	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.